Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus PREMPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus PREMPRO.
NORGESTIMATE AND ETHINYL ESTRADIOL vs PREMPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via estrogen receptor; norgestimate is a progestin that inhibits ovulation and thickens cervical mucus.
PREMPRO is a combination of conjugated estrogens and medroxyprogesterone acetate. Estrogens bind to estrogen receptors, activating gene transcription and exerting effects on various tissues. Medroxyprogesterone acetate is a progestin that suppresses endometrial proliferation, reducing the risk of endometrial hyperplasia associated with unopposed estrogen therapy.
One tablet (norgestimate 0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days followed by 7 placebo tablets.
One tablet orally once daily; each tablet contains conjugated estrogens 0.625 mg and medroxyprogesterone acetate 2.5 mg or 5 mg.
None Documented
None Documented
Norgestimate: ~21.3 hours (range 16-36 hours); active metabolite 17-deacetyl norgestimate: ~33.2 hours (range 22-45 hours). Ethinyl estradiol: ~17.1 hours (range 14-22 hours). Terminal half-life supports once-daily dosing; steady-state achieved within 10-14 days.
The terminal elimination half-life of conjugated estrogens (primarily estrone and equilin) ranges from 10-24 hours (mean ~15 hours) after oral administration. This supports once-daily dosing with steady-state achieved within 5-7 days.
Urine (primarily as glucuronide and sulfate conjugates; ~50-60% of dose), feces (~30-40% of dose as metabolites), minimal unchanged drug in urine
Conjugated estrogens are primarily excreted in urine (renal elimination accounts for ~50-80% of total clearance) as glucuronide and sulfate conjugates. A smaller fraction undergoes biliary excretion (~10-20%) and is eliminated in feces via enterohepatic circulation.
Category D/X
Category C
Estrogen
Estrogen/Progestin Combination